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ABSTRACT: The beneﬁts of high ﬁeld asymmetric waveform ion
mobility spectrometry (FAIMS) for mass spectrometry imaging of
intact proteins in thin tissue sections have been demonstrated
previously. In those works, a planar FAIMS device coupled with a
Thermo Elite mass spectrometer was employed. Here, we have
evaluated a newly introduced cylindrical FAIMS device (the
FAIMS Pro) coupled with a Thermo Fusion Lumos mass
spectrometer for liquid extraction surface analysis mass spectrom-
etry imaging of intact proteins in thin tissue sections from rat
testes, kidney, and brain. The method makes use of multiple
FAIMS compensation values at each location (pixel) of the
imaging array. A total of 975 nonredundant protein species were
detected in the testes imaging dataset, 981 in the kidney dataset,
and 249 in the brain dataset. These numbers represent a 7-fold (brain) and over 10-fold (testes, kidney) improvement on the
numbers of proteins previously detected in LESA FAIMS imaging, and a 10-fold to over 20-fold improvement on the numbers
detected without FAIMS on this higher performance mass spectrometer, approaching the same order of magnitude as those obtained
in top-down proteomics of cell lines. Nevertheless, high throughput identiﬁcation within the LESA FAIMS imaging workﬂow
remains a challenge.
Liquid extraction surface analysis (LESA)1 is an ambientmass spectrometry technique which is particularly well
suited to the analysis of intact proteins from a range of
biological substrates including thin tissue sections. The beneﬁts
of interrogation of intact proteins rather than their proteolytic
peptides include retention of all information relating to
primary structure, including single nucleotide polymorphisms,
and presence and connectivity of post-translational modiﬁca-
tions. A challenge for LESA of thin tissue sections is the
inherent complexity of the extracted sample. That challenge
can be addressed through integration of ion mobility
separation, such as high ﬁeld asymmetric waveform ion
mobility spectrometry2,3 (FAIMS; also known as diﬀerential
mobility spectrometry (DMS)), in the workﬂow. FAIMS
separates gas-phase ions at atmospheric pressure by exploiting
diﬀerences in their mobilities in high and low electric ﬁelds.
Ions are passed between parallel electrodes, to which an
asymmetric waveform is applied, by a carrier gas. As a result of
their diﬀerential mobilities, the ions will deviate from their
original trajectory. This deviation can be corrected by
superposition of a dc compensation voltage (CV). It is
possible to selectively transmit ions of particular diﬀerential
mobility by tuning the CV.
Mass spectrometry imaging (MSI)4 provides information on
the spatial distribution of analytes across substrates such as a
thin tissue sections, allowing insights into analyte colocaliza-
tion and the molecular basis of tissue features. We have
previously demonstrated LESA FAIMS mass spectrometry
imaging of intact proteins in sections of mouse brain and
mouse liver.5 At each tissue location in the imaging array, the
CV was kept constant. In that work, ∼30 proteins were
detected in each tissue type. We subsequently demonstrated
LESA FAIMS MSI of thin tissue sections from rat kidney and
testes, in which multiple CV settings were employed for
analysis at each tissue location.6 That approach enabled
detection of ∼60 intact proteins from the kidney samples and
∼75 for the testes samples. Both of these previous studies
made use of a planar miniaturized ultrahigh ﬁeld FAIMS device
and a Thermo Elite orbitrap mass spectrometer. Recently, a
cylindrical FAIMS device (FAIMS Pro) has been introduced
which oﬀers improved ion mobility resolution and high
transmission eﬃciency.7,8 FAIMS Pro has been shown to be
advantageous for bottom-up proteomic analyses, when coupled
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with liquid chromatography tandem mass spectrometry (LC-
MS/MS), by improving signal-to-noise and extending
proteome coverage.9,10 Here, we have performed LESA
FAIMS MSI of intact proteins in thin tissue sections of rat
testes, kidney, and brain by use of the FAIMS Pro coupled with
a Thermo Fusion Lumos mass spectrometer and demonstrate
signiﬁcant improvements in the numbers of proteins detected.
The results are applicable not only for mass spectrometry
imaging of intact proteins but also more generally for top-
down proteomics experiments11,12 in which complex mixtures
of intact proteins isolated from cell lines or homogenized tissue
are analyzed by liquid chromatography tandem mass
spectrometry.
■ METHODS
Samples. Rat tissue was the kind gift of Dr. Richard
Goodwin (AstraZeneca). Brain, testes, and kidney tissues were
obtained from control (vehicle-dosed) male Hans Wistar rats.
Animals were euthanized by cardiac puncture under isoﬂuor-
ane anesthetic 2 h post dose. All tissue dissection was
performed by trained AstraZeneca staﬀ (project license 40/
3484, procedure number 10). Tissues were snap frozen in dry
ice chilled isopentane and stored at −80 °C. Tissues were
subsequently cryosectioned at a thickness of 10 μm using a
CM1810 Cryostat (Leica Microsystems, Wetzlar, Germany)
and thaw mounted onto glass slides.
Acetonitrile, ethanol, water (all Optima LC/MS grade), and
formic acid were purchased from Fisher Scientiﬁc (Waltham,
MA).
LESA. Rat brain sections were prewashed in 70% ethanol for
10 s (to remove abundant lipid species) before air drying and
loading onto a universal LESA adapter plate. Other tissue
sections (which do not contain similarly high levels of lipids)
were not prewashed. Samples were placed into the TriVersa
Nanomate chip-based electrospray device (Advion, Ithaca,
NY). The extraction/ionization solvent comprised 40:60
acetonitrile:water with 1% formic acid. Contact-LESA13 was
performed as follows: 4 μL of solvent was aspirated, and 2 μL
was dispensed onto the sample for 10 s before 2.5 μL was
reaspirated. Samples were mixed twice and introduced into the
mass spectrometer via the TriVersa NanoMate with gas
pressure of 0.3 psi and tip voltage of 1.70 kV. All MSI
experiments were acquired at 1 mm × 1 mm spacing.
FAIMS Mass Spectrometry Imaging. The Triversa
Nanomate was coupled to a Thermo Fisher FAIMS Pro
device (Thermo Fisher Scientiﬁc, San Jose, CA) which was
coupled to a Thermo Fisher Fusion Lumos mass spectrometer
(Thermo Fisher Scientiﬁc, San Jose, CA). The FAIMS
dispersion voltage (DV) was −5 kV. For each tissue type,
optimization experiments were performed in which the
compensation voltage (CV) was stepped in 10 V increments
from −120 to +50 V. For each imaging experiment, multistep
compensation workﬂows (optimized for tissue type) were
applied. At each location in the testes imaging data set, data
were acquired for 30 s with the FAIMS voltages oﬀ, followed
by 30 s at each of CV = −70, −60, −50, −40, −30, and −20 V,
and a ﬁnal 30 s with the FAIMS voltages oﬀ, for a total
acquisition time of 4 min. For the kidney data set, data were
acquired for 30 s with the FAIMS voltages oﬀ, followed by 30 s
at each of CV = −80, −70, −60, −50, −40, and −30 V, and a
ﬁnal 30 s with the FAIMS voltages oﬀ, for a total acquisition
time of 4 min/location. For the brain data set, data were
acquired for 30 s with the FAIMS voltages oﬀ, followed by 30 s
at each of CV = −90, −80, −70, and −60, and a ﬁnal 30 s with
the FAIMS voltages oﬀ, for a total acquisition time of 3 min/
location. Mass spectra were recorded in full scan mode at a
resolution of 120 000 at m/z 200 in the m/z range of 350−
2000. To avoid imaging bias introduced by use of automated
gain control (AGC), an AGC target of 5 × 106 charges and a
maximum injection time of 100 ms was applied. (The
combination of extremely high AGC target and moderate
injection time ensures that the AGC target is never reached,
and each scan comprises identical accumulation times (i.e., 100
ms)). Each scan was comprised of ﬁve coadded microscans.
For top-down MS/MS experiments, electron transfer high-
energy collision-induced dissociation (EThcD) was performed.
For precursor m/z 661, the ETD reaction time was 20 ms, and
HCD was performed at 15% normalized collision energy
(NCE). The MS/MS spectrum comprises 80 scans. For
precursors m/z 706 and 558, the ETD reaction time was 10
ms, and HCD was performed at 30% NCE. The MS/MS
spectra comprise 20 and 12 scans, respectively. For precursor
m/z 1036, the ETD reaction time was 20 ms, and CID was
performed at 30% NCE. The MS/MS spectrum comprises 15
scans.
Data Analysis. Data were analyzed by use of Xcalibur
software and BioPharma Finder 3.1 (both Thermo Fisher
Scientiﬁc). All mass spectra were deconvoluted using the
Xtract algorithm in BioPharma Finder in the batch processing
mode. Source spectra were deﬁned by the “Average Over
Selected Retention Time” method in which the RT range
correlated with the data acquisition time at each CV. That is,
for each pixel, multiple deconvolutions were performed, each
of which corresponded to a particular CV. The parameters for
the search were a minimum signal-to-noise ratio of 3 (“FAIMS
on”) or 4 (“FAIMS oﬀ”) and a ﬁt factor of 80%. All other
settings were left as default. Output masses were reported as
the neutral species M. The resulting output ﬁles were collated
in MATLAB (version 2013a, The MathWorks Inc., Natick,
MA) such that a list of all unique detected masses and their
frequency of occurrence was produced (see File S1, File S2,
and File S3 of the Supporting Information). Masses detected
across multiple CV steps and/or locations and within a
tolerance of 0.5 Da were considered as a single (mean) mass.
The noise level was determined using the median of the
frequency, and masses which had a signal-to-noise ratio ≤3
were discarded.
For image generation, single location .raw data ﬁles were
converted to .mzML using MS convert and then converted to
the imzML format and loaded into MATLAB using
imzMLConverter14 and SpectralAnalysis software.15 t-SNE
plots were generated using Python 3.7 and the SciKitLearn
library.16 Prior to embedding, spectra were linearly interpo-
lated and median normalized. t-SNE parameters were as
follows: perplexity = 35, initialization = random, learning rate =
500, early exaggeration = 10. The distance metric was
Euclidean. UpSet plots were created using the UpSet R
package.17
Top-down protein identiﬁcation was performed with
ProSightPC software, version 3.0 (Thermo Fisher Scientiﬁc,
Bremen, Germany). MS/MS spectra were deconvoluted by the
THRASH algorithm at a signal-to-noise ratio of 3 and matched
against the Rattus norvegicus database available via UniProt.
Putative protein assignments were conﬁrmed by manual
analysis, in which experimental fragment m/z values were
compared with theoretical m/z values calculated by Protein
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Prospector (http://prospector.ucsf.edu/) and sequence cover-
ages calculated.
■ RESULTS AND DISCUSSION
Thin tissue sections of rat testes, kidney, and brain were
subjected to LESA FAIMS MSI. The workﬂow is shown in
Figure S1 of the Supporting Information. For each dataset, the
mass spectra obtained at each CV value at each location (pixel)
were deconvoluted using the Xtract algorithm in the
BioPharma Finder software resulting in multiple lists of intact
protein masses associated with each CV/location. To
determine the total number of intact protein masses detected
across the entire image, or within a single pixel, masses
detected within multiple CV steps and/or locations that fell
within a tolerance of 0.5 Da were considered as a single
(mean) mass. (Although the Biopharma Finder software does
oﬀer the facility for Multiconsensus reporting, i.e., merging the
deconvolution results from multiple raw ﬁles, which would in
principle remove the requirement for this step, it is limited to a
maximum of 10 data ﬁles. This limit is incompatible with a
FAIMS MSI data set. For example, the kidney image data set
comprised 117 pixels, with six CV steps, i.e., a total of 702 data
ﬁles). Concatenated mass lists (either entire image or single
pixel) were ﬁltered such that all masses that were detected with
a frequency S/N of ≤3 were discarded. Noise levels diﬀered
between tissue types and for the FAIMS data were determined
to be 4 (testes), 8 (kidney), and 1 (brain). For “FAIMS
voltages oﬀ” data, the noise levels were 1 (testes), 2 (kidney),
and 2 (brain). It is important to note that the Xtract algorithm
does not take into account the presence of adducts; therefore,
the numbers of proteins reported herein include both
proteoforms and any adducts thereof (e.g., sodium or
potassium adducts) that may be present. A potential solution
would be software that enables removal of adducts by
consideration of exact mass shifts, an approach that is
commonly applied in metabolomics studies; however, this
approach would require retention of accurate masses in the
deconvolution step. We have used a broad tolerance (±0.5 Da)
to prevent overestimation of protein numbers; however,
further development of the deconvolution software itself (i.e.,
raising the limit of data ﬁles allowable for multiconsensus
reporting) might enable this approach to be implemented.
The total number of proteins detected across the entire
testes imaging data set (FAIMS on) was 975, with a mean of
517 proteins detected at each CV. The number of proteins
detected across the imaging data set when the FAIMS voltages
were oﬀ was 48. (It is worth noting that in a previous study of
LESA planar FAIMS MS of fresh frozen rat testes the number
of proteins detected when the FAIMS voltages were oﬀ was
ﬁve.6 The improvement observed here when the FAIMS
voltages were oﬀ is due to the improved performance of the
mass spectrometer). The molecular weight range was from 1.8
Figure 1. LESA FAIMS MSI of thin tissue sections from testes, kidney, and brain. (A), (D), (G) Distribution of protein masses across CV values.
(B), (E), (H) t-SNE plot of LESA FAIMS MSI data. Each point corresponds to a pixel at a particular CV value. (C), (F), (I) Overlay of the mass
spectra obtained at the diﬀerent CV values for pixel 59 (testes), pixel 70 (kidney), and pixel 35 (brain).
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to 21 kDa (File S1, Supporting Information). The distribution
of proteins across CV values is shown in Figure 1a. The
overlap in protein masses at the various CV values is shown in
the UpSet plot in Figure S2 of the Supporting Information.17
The greatest overlap was 72 proteins, corresponding to 7.4% of
the total proteins, detected at CV = −20, −30, −40, and −50
V. The majority of the proteins (54%) were observed at ≤3
CV values. The complementarity of the various CV steps and
therefore the beneﬁts of FAIMS integration can be further
visualized by t-distributed stochastic neighbor embedding (t-
SNE) (Figure 1b). Each point corresponds to a pixel at a
particular CV value, or in the absence of FAIMS. There is clear
separation between the CV values. The various CV values are
also generally clearly separated from the “FAIMS voltages oﬀ”
data, with some similarity between “FAIMS voltages oﬀ” and
CV = −30 V and CV = −40 V. Figure 1c shows an overlay of
the mass spectra obtained at the diﬀerent CV values for a
representative pixel (pixel 59). For that pixel, the total number
of proteins detected was 382 (FAIMS voltages on) and 5
(FAIMS voltages oﬀ).
Similar analyses were performed for the kidney and brain
imaging data sets (Figure 1d−i). For kidney, a total of 981
proteins were detected across the entire imaging data set with
the “FAIMS on” compared with 44 with the “FAIMS oﬀ”. The
molecular weight range was from 1.7 to 18 kDa (File S2,
Supporting Information). The UpSet plot (Figure S3,
Supporting Information) reveals that the majority of the
proteins (90%) were detected at three or fewer CV values, and
the greatest overlap was 203 proteins (21% of total proteins
detected) observed at CVs = −30, −40, and −50 V. t-SNE
reveals clear separation between the CV values, and the
greatest similarity between the “FAIMS oﬀ” and CV= −40 V.
For brain, a total of 249 proteins were detected across the
entire imaging data set with FAIMS voltages on, and 21
proteins were detected with FAIMS voltages oﬀ. The
molecular weight range was from 2.2 to 19 kDa (File S3,
Supporting Information). The UpSet plot (Figure S4,
Supporting Information) reveals that 65% of proteins were
detected at individual CV values. The greatest set overlap
(18%) was observed for CVs = −60 and −70 V. t-SNE reveals
clear separation between the various CV values and the
“FAIMS voltages oﬀ” data. Within CV values, CVs = −60 and
−70 V are clearly separated, and CVs = −80 and −90 V show
the greatest similarity.
A well-established advantage of mass spectrometry imaging
is its broad speciﬁcity: There is no requirement for a priori
knowledge of the analyte to be imaged, and ion images may be
generated for any ion detected. Clearly, the greater the
sensitivity of the imaging technique is, the greater the
possibilities are for mining the imaging data set (i.e., the
greater the number of analytes that can be imaged). To
illustrate, Figure 2 shows a mass spectrum obtained at CV =
−60 V from a single location within the testes data set,
together with example ion images. As mentioned above, the
Figure 2. LESA FAIMS MSI of section of testes. Mass spectrum obtained at CV = −60 V for pixel 58. Inset: example ion images and photograph of
tissue section after LESA sampling.
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total analysis time per pixel was 4 min for the testes and kidney
samples and 3 min for the brain sample. The total image
acquisition times were 624 min (testes), 468 min (kidney),
and 252 min (brain). Previous LESA FAIMS MSI5,6 using the
planar FAIMS device had single pixel analyses times of 1−2
min but were limited to one or two CV steps. Although the
image acquisition time is longer in the current work, that
feature is oﬀset by the improved numbers of proteins detected.
The protein numbers reported here are a signiﬁcant
improvement (over 10-fold for testes and kidney and 7-fold
for brain) on those previously reported for intact protein
FAIMS MSI5,6,18 and approach the same order of magnitude as
those obtained in top-down proteomics of protein extracted
from cell lines.19,20 In those studies, the extracted proteins
were separated by gel-eluted liquid fraction entrapment
electrophoresis (GELFrEE) prior to liquid chromatography
MS using a 90 min gradient. Here, the MS analysis time at
each pixel was 3 or 4 min. It is also useful to consider the
numbers of proteins detected with those obtained in bottom-
up proteomics studies of homogenized tissue. For example, we
detected 981 proteins in kidney, which compares well with the
991 quantiﬁable proteins detected in a recent proteomic
analysis of rat kidney;21 however, the number of testes proteins
detected here is approximately 10% of those recently reported
in a bottom-up proteomics study of homogenized testis
tissue.22
Although the numbers of proteins detected here may be
comparable to top-down or bottom-up proteomics studies, it is
important to note that in the proteomics studies the proteins
are identif ied. Protein identiﬁcation is a challenge for intact
protein MSI. Typically, LESA MSI of a thin tissue section is
followed by LESA sampling of an adjacent tissue section and
top-down tandem mass spectrometry. We applied that
approach to several of the protein ions detected here, focusing
speciﬁcally on ions that have not been detected in previous
LESA or LESA FAIMS analyses of thin tissue sections. For
example, 14+ ions with m/z 661 (MWmeas 9242 Da) detected
at CV = −50 V in kidney were selected for electron transfer
higher energy collision dissociation (EThcD) (Figure S5,
Supporting Information). The protein was identiﬁed as high
mobility group nucleosomal binding domain 2 (HMGN2)
with a sequence coverage of 25%. A protein with this molecular
weight has been observed previously by LESA FAIMS MSI;
however, it was not identiﬁed.6 Three ions were selected for
EThcD from the testis tissue (Figure S6, Supporting
Information) and identiﬁed as β-thymosin 10 (with N-
terminus acetylation; sequence coverage 63%), a 24 amino
acid peptide fragment arising from the N-terminal region of
serum albumin (sequence coverage 91%), and a phosphatidyl-
ethanolamine binding protein (with N-terminus acetylation;
sequence coverage 8%). This low-throughput approach is
clearly not compatible with the hundreds of proteins detected
and is a limitation that will need to be addressed. One
approach perhaps is to perform unsupervised multivariate
analysis followed by targeted identiﬁcation of the diﬀer-
entiating proteins. Alternatively, a data-independent approach,
whereby all protein ions detected are fragmented simulta-
neously, could be developed.
■ CONCLUSION
Integration of the cylindrical FAIMS Pro device in the LESA
mass spectrometry imaging workﬂow results in signiﬁcant
improvements in the number of proteins detected (over 10-
fold for testes and kidney and 7-fold for brain) when compared
with previous LESA FAIMS imaging in which a planar FAIMS
device was employed. For testes and kidney, the improvement
in protein numbers detected between “FAIMS voltages on”
and “FAIMS voltages oﬀ” was over 20-fold, with an over 10-
fold improvement observed for brain. The beneﬁts of FAIMS
and complementarity of results obtained at various CV values
was visualized through use of UpSet plots and t-SNE.
Currently, the LESA FAIMS MSI workﬂow does not lend
itself to high throughput identiﬁcation of proteins; never-
theless, we employed LESA EThcD MS/MS on adjacent tissue
sections to assign three previously unidentiﬁed proteins.
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